Kaushal Neha, Baranwal Manoj
Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.
Biotechnol Appl Biochem. 2025 Apr;72(2):498-512. doi: 10.1002/bab.2679. Epub 2024 Oct 14.
Crimean-Congo hemorrhagic fever virus (CCHFV) belongs to Nairoviridae family and has tripartite RNA genome. It is endemic in various countries of Asia, Africa, and Europe and is primarily transmitted by Hyalomma ticks but nosocomial transmission also been reported. Vaccines for CCHF are in early phase of clinical trial; therefore, this work is centered on identification of potential immunogenic peptide as vaccine candidates with application of different immunoinformatics approaches. Eleven conserved (>90%) peptides of CCHFV nucleoprotein were selected for CD8 T-cell (NetMHCpan 4.1b and NetCTLpan 1.1 server) and CD4 T-cell (NetMHCIIpan-4.0 server and Tepitool) epitope prediction. Three peptides containing multiple CD8 and CD4 T-cell and B-cell epitopes were identified on basis of consensus prediction approach. Peptides displayed good antigenicity score of 0.45-0.68 and predicted to bind with diverse human leukocyte antigen (HLA) alleles. Molecular docking was performed with epitopes to HLA and HLA-epitopes complex to T-cell receptor (TCR). In most of the cases, docked complex of HLA-epitope and HLA-epitopes-TCR have the binding energy close to respective natural bound peptide complex with HLA and TCR. Molecular dynamic simulation also revealed that HLA-peptide complexes have minimum fluctuation and deviation than HLA-peptide-TCR docked over 50 ns simulation run. Considering these findings, identified peptides can serve as potential vaccine candidates for CCHFV disease.
克里米亚-刚果出血热病毒(CCHFV)属于内罗病毒科,具有三分体RNA基因组。它在亚洲、非洲和欧洲的多个国家流行,主要通过璃眼蜱传播,但也有医院内传播的报道。CCHF疫苗正处于临床试验的早期阶段;因此,这项工作的重点是应用不同的免疫信息学方法,鉴定潜在的免疫原性肽作为疫苗候选物。选择了CCHFV核蛋白的11个保守(>90%)肽段,用于CD8 T细胞(NetMHCpan 4.1b和NetCTLpan 1.1服务器)和CD4 T细胞(NetMHCIIpan-4.0服务器和Tepitool)表位预测。基于共识预测方法,鉴定出了三个含有多个CD8和CD4 T细胞以及B细胞表位的肽段。这些肽段的抗原性评分良好,为0.45-0.68,并预计能与多种人类白细胞抗原(HLA)等位基因结合。对表位与HLA以及HLA-表位复合物与T细胞受体(TCR)进行了分子对接。在大多数情况下,HLA-表位和HLA-表位-TCR的对接复合物的结合能接近各自与HLA和TCR的天然结合肽复合物。分子动力学模拟还显示,在50纳秒的模拟运行中,HLA-肽复合物的波动和偏差比HLA-肽-TCR复合物小。考虑到这些发现,鉴定出的肽段可作为CCHFV疾病的潜在疫苗候选物。